Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satpathy

Showing results (821-830 of 985) with videos related to

Pageof 99
Sort By:
BMJ Global Health|November 1, 2022
Risk factors for community-acquired bacterial infection among young infants in South Asia: a longitudinal cohort study with nested case-control analysisNicholas E Connor, Mohammad Shahidul Islam, Luke C Mullany, et al.
Cancer Discovery|August 24, 2022
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Eric J Jaehnig, Karsten Krug, et al.
Nature|June 15, 2018
Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Nature|November 8, 2023
Latent human herpesvirus 6 is reactivated in CAR T cellsCaleb A Lareau, Yajie Yin, Katie Maurer, et al.
Nature|August 31, 2017
Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Cancer Cell|December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicitySabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
Science (New York, N.Y.)|March 8, 2022
KIR<sup>+</sup>CD8<sup>+</sup> T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19Jing Li, Maxim Zaslavsky, Yapeng Su, et al.
Cancer Cell|March 28, 2025
Translation dysregulation in cancer as a source for targetable antigensChen Weller, Osnat Bartok, Christopher S McGinnis, et al.
Nature Communications|November 2, 2019
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathwaysElena López-Isac, Marialbert Acosta-Herrera, Martin Kerick, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Pageof 99

Showing results (821-830 of 985) with videos related to

Sort By:
Pageof 99
BMJ Global Health|November 1, 2022
Risk factors for community-acquired bacterial infection among young infants in South Asia: a longitudinal cohort study with nested case-control analysisNicholas E Connor, Mohammad Shahidul Islam, Luke C Mullany, et al.
Cancer Discovery|August 24, 2022
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast CancerMeenakshi Anurag, Eric J Jaehnig, Karsten Krug, et al.
Nature|June 15, 2018
Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Nature|November 8, 2023
Latent human herpesvirus 6 is reactivated in CAR T cellsCaleb A Lareau, Yajie Yin, Katie Maurer, et al.
Nature|August 31, 2017
Discovery of stimulation-responsive immune enhancers with CRISPR activationDimitre R Simeonov, Benjamin G Gowen, Mandy Boontanrart, et al.
Cancer Cell|December 31, 2021
GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicitySabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, et al.
Science (New York, N.Y.)|March 8, 2022
KIR<sup>+</sup>CD8<sup>+</sup> T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19Jing Li, Maxim Zaslavsky, Yapeng Su, et al.
Cancer Cell|March 28, 2025
Translation dysregulation in cancer as a source for targetable antigensChen Weller, Osnat Bartok, Christopher S McGinnis, et al.
Nature Communications|November 2, 2019
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathwaysElena López-Isac, Marialbert Acosta-Herrera, Martin Kerick, et al.
Science (New York, N.Y.)|February 8, 2020
CRISPR-engineered T cells in patients with refractory cancerEdward A Stadtmauer, Joseph A Fraietta, Megan M Davis, et al.
Pageof 99